Dataset Information


The HDAC inhibitor panobinostat (LBH589) inhibits Acute Lymphoblastic leukemia (ALL) in vitro and in vivo in a new characterized human ALL mice model (ALL-B and ALL-T)

ABSTRACT: Histone deacetylases (HDACs) have been identified as therapeutic targets due to regulatory function in DNA structure and organization. We have analyzed the role of the LBH589, a novel pan inhibitor of class I and II HDACs, in Acute Lymphoblastic Leukemia. In vitro, LBH589 was shown to induce a dose dependent antiproliferative and apoptotic effect which was associated with an increase in the acetylation of H3 and H4 histone acetylation which was uniformly in every genetic subgroup of ALL. In vivo administration of LBH589 in BALB/c-RAG2-/-γc-/- mice in which T and B-cell leukemic cell lines were injected induced a significant reduction in tumor growth (TOM-1, p<0.01 and MOLT-4 p<0.05). Leukemic cells from patients were employed to establish a xenograft model of human leukemia in BALB/c-RAG2-/-γc-/- mice and further transplanted in consecutive generations of mice. Treatment of these xenografts with LBH589 induced an increase in the acetylation of H3 and H4 and prolonged the survival of mice in comparison with the animals treated with Vincristine and Dexametasone (p<0.05) and this effect was significantly higher when LBH589 was combined with Vincristine and Dexametasone (p<0.001). Our results that the use of LBH589 in combination with standard chemotherapy represents an attractive option for treatment of patients with ALL. Two primary samples of ALL (one ALL-B and one ALL-T) and two samples of each leukemia after passages in immunodeficient mice.

ORGANISM(S): Homo sapiens  

SUBMITTER: Felipe Prósper   Cristina Moreno  Jose A Martinez-Climent  Alba D Rodriguez  María Blanco-Prieto5  José Rifón  Juan C Cigudosa  María J Calasanz  Amaia Vilas-Zornoza  José Román-Gómez  Gloria Abizanda  Jose A García de Jalón  Edurne San José-Eneriz  Victor Segura  Xabier Agirre 

PROVIDER: E-GEOD-26789 | ArrayExpress | 2012-04-17



altmetric image


Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here, we analyzed the therapeutic effect of LBH589, a class I-II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation. Intravenous administration of LBH589 in immunodeficient BALB/c-RAG2(-/-)γc(-/-) mice  ...[more]

Similar Datasets

2012-04-18 | GSE26790 | GEO
2012-04-17 | E-GEOD-26791 | ArrayExpress
2012-04-17 | E-GEOD-26792 | ArrayExpress
2012-04-17 | E-GEOD-26790 | ArrayExpress
2015-09-16 | E-GEOD-26790 | ExpressionAtlas
2012-01-01 | S-EPMC3417119 | BioStudies
2017-01-01 | S-EPMC5353903 | BioStudies
2016-02-16 | E-GEOD-57785 | ArrayExpress
1000-01-01 | S-EPMC2384136 | BioStudies
2017-01-01 | S-EPMC6063353 | BioStudies